-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALKS-2680 in Idiopathic Hypersomnia (IH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALKS-2680 in Idiopathic Hypersomnia (IH) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALKS-2680 in Idiopathic Hypersomnia (IH) Drug Details: ALKS-2680 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALKS-2680 in Type 1 Narcolepsy (Narcolepsy with Cataplexy)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALKS-2680 in Type 1 Narcolepsy (Narcolepsy with Cataplexy) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALKS-2680 in Type 1 Narcolepsy (Narcolepsy with...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALKS-2680 in Type 2 Narcolepsy (Narcolepsy without Cataplexy)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALKS-2680 in Type 2 Narcolepsy (Narcolepsy without Cataplexy) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALKS-2680 in Type 2 Narcolepsy (Narcolepsy without...
-
Product Insights
Likelihood of Approval Analysis for Epilepsy
Overview How likely is it that the drugs in Epilepsy will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Epilepsy Overview Epilepsy is a group of non-communicable neurological disorders characterized by recurrent...
-
Product Insights
NewNarcolepsy – Drugs In Development, 2024
Empower your strategies with our Narcolepsy – Drugs In Development, 2024 report and make more profitable business decisions. Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy, hallucinations, and sleep paralysis. Narcolepsy treatment includes lifestyle changes, medication, and counseling. The Narcolepsy drugs in development market research report provide comprehensive information on the therapeutics under development for Narcolepsy, complete with analysis by stage of development, drug target, mechanism...
-
Product Insights
NewHypersomnia – Drugs In Development, 2024
Empower your strategies with our Hypersomnia – Drugs In Development, 2024 report and make more profitable business decisions. Hypersomnia is a neurological disorder of excessive time spent sleeping or excessive sleepiness. It can have many possible causes (such as seasonal affective disorder) and can cause distress and problems with functioning. It is a pathological state characterized by a lack of alertness during the waking episodes of the day. The main symptom of hypersomnia is excessive daytime sleepiness (EDS), or prolonged nighttime...
-
Product Insights
Peripheral Artery Occlusive Disease (PAOD) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Peripheral Artery Occlusive Disease (PAOD) Clinical Trials Overview The Peripheral Artery Occlusive Disease (PAOD) clinical trial report consists of 1328 trials. The report provides an overview of the Peripheral Artery Occlusive Disease (PAOD) clinical trial scenario. Our study also includes top-line data relating to the clinical trials on Peripheral Artery Occlusive Disease (PAOD), in this report. Our analysts have further provided an overview of trial numbers and their average enrolment in top countries conducted across the globe. Furthermore, our review...
-
Product Insights
Cardiac Marker Tests Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Cardiac Marker Tests Pipeline Market Overview A cardiac marker test is a biomarker test used to diagnose cardiac diseases. The Cardiac Marker Tests pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Segments ·       Other Cardiac Marker...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Teicoplanin in Cystic Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Teicoplanin in Cystic Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Teicoplanin in Cystic Fibrosis Drug Details:Teicoplanin is under development for the treatment of...